Phase 3 Clinical Trials With Primary Completion Dates in October 2017

This is a list of Phase 3 trials with primary completion dates in October 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ARDX Ardelyx, Inc. 2017-10-01 Phase 3 NCT02727751 A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C
CPRX Catalyst Pharmaceuticals, Inc. 2017-10-01 Phase 3 NCT02562066 Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
EARS Auris Medical Holding AG 2017-10-01 Phase 3 NCT02561091 AM-111 in the Treatment of Acute Inner Ear Hearing Loss
INSM Insmed, Inc. 2017-10-01 Phase 3 NCT02344004 Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone
MNK Mallinckrodt plc 2017-10-01 Phase 3 NCT02132195 Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome
NBRV Nabriva Therapeutics plc 2017-10-01 Phase 3 NCT02813694 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
TARO Taro Pharmaceutical Industries Ltd. 2017-10-01 Phase 3 NCT02595073 Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis
TGTX TG Therapeutics, Inc. 2017-10-01 Phase 3 NCT02301156 Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
VICL Vical Incorporated 2017-10-01 Phase 3 NCT01877655 A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)